Inspiration Healthcare Group PLC SLE 6000 & OxyGenie(R) Japan approval & GBP400k Order (3165S)

TIDMIHC

RNS Number : 3165S

Inspiration Healthcare Group PLC

16 March 2021

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

SLE 6000 and OxyGenie (R) approved for use in Japan

with initial order for c.GBP400,000

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, is pleased to announce that SLE Ltd, the specialist neonatal ventilator manufacturer it acquired in July 2020, has received Japanese regulatory approval for the enhanced SLE6000. The approval is for the top of the range SLE6000 model that includes various features such as enhanced High Frequency Oscillatory Ventilation designed for use with critically ill infants as well as the OxyGenie (R) patented oxygen control algorithm which helps maintain infants at their targeted oxygen saturation levels, volume targeted ventilation, End-Tidal CO(2) monitoring and greater non-invasive modes. This product has been registered for use in Japan and the Company's Japanese distributor has placed an initial order totalling c.GBP400,000 for immediate despatch.

Neil Campbell, Chief Executive Officer, commented: "We are delighted to have received this significant order and the successful registration of these products in Japan and to see that our global reach continues to expand as the advanced technologies we have developed are adopted in the leading neonatal Intensive care units all over the world."

Enquiries:

 
 Inspiration Healthcare Group plc          Tel: [phone] 
  Neil Campbell, Chief Executive Officer 
  Jon Ballard, Chief Financial Officer 
 Nominated Adviser & Broker                Tel: [phone] 
  Cenkos Securities plc 
  Mark Connelly 
  Stephen Keys 
                                          ------------------- 
 Cadogan PR                                Tel: [phone] 
  Alex Walters 
  [e-mail] 
                                          ------------------- 
 
   About Inspiration Healthcare   http://www.inspiration-healthcare.com 

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in critical care & operating theatres. The Company provides high-quality, innovative products to patients around the world which help to improve patient outcomes, and it actively invests in innovative product opportunities and disruptive technologies.

Through investment in research and development the Company has six key own-brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally, the Company has a range of products for maintaining normothermia pre- during and post-surgery.

In September 2019, the Company acquired Vio Holdings a designer, manufacturer and supplier of single-use respiratory products and sterile medical consumables for GBP3.7 million and in June 2020 the Company acquired SLE, a leading global provider of neonatal ventilation products for GBP18 million. Over 90% of SLE's revenues are generated from sales outside of the UK with a significant proportion of these in the Asia Pacific and the Middle East. When combined, the Group generates approximately 60 per cent. of its revenue from exports.

With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.

In the U.K. and Ireland, the Company has a direct sales team selling Inspiration Healthcare Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.

   Further information on Inspiration Healthcare can be seen at   www.inspiration-healthcare.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

REAFZGMFVKVGMZM

(END) Dow Jones Newswires

March 16, 2021 03:00 ET (07:00 GMT)